Gastroesophageal Junction Clinical Trials in Shanghai, Shanghai Municipality
22 recruitingShanghai, Shanghai Municipality, China
Showing 1–20 of 22 trials
Recruiting
Phase 1Phase 2
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC210 enrolled44 locationsNCT06445972
Recruiting
Phase 1Phase 2
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC160 enrolled50 locationsNCT06469944
Recruiting
Phase 3
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.500 enrolled224 locationsNCT06901531
Recruiting
Phase 1
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Gastric AdenocarcinomaPancreatic AdenocarcinomaGastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.398 enrolled45 locationsNCT05365581
Recruiting
Phase 2Phase 3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb690 enrolled160 locationsNCT07221149
Recruiting
Phase 2
A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Fudan University276 enrolled1 locationNCT07492615
Recruiting
Phase 1
HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Hansoh BioMedical R&D Company40 enrolled1 locationNCT07462923
Recruiting
Phase 1
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Gastric CancerEsophageal AdenocarcinomaMetastatic Cancer+5 more
I-Mab Biopharma US Limited330 enrolled21 locationsNCT04900818
Recruiting
Phase 2
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.258 enrolled1 locationNCT05671822
Recruiting
Phase 3
A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.600 enrolled2 locationsNCT07118527
Recruiting
Phase 3
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Akeso760 enrolled6 locationsNCT07023315
Recruiting
Phase 3
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma
Gastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd.490 enrolled2 locationsNCT07152405
Recruiting
Phase 2
A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd.40 enrolled1 locationNCT06423885
Recruiting
Phase 2
Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Ruijin Hospital30 enrolled1 locationNCT07026149
Recruiting
The Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer
Gastric Cancer, Gastroesophageal Junction Cancer
Fudan University600 enrolled1 locationNCT06786169
Recruiting
Phase 2
A Phase 2 Clinical Study of ABSK061 and ABSK043
Urothelial CarcinomaHER2-Gastric/Gastroesophageal Junction Cancer
Abbisko Therapeutics Co, Ltd202 enrolled21 locationsNCT06632262
Recruiting
Phase 2
The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Zhongshan Hospital50 enrolled1 locationNCT06587425
Recruiting
Phase 2Phase 3
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Gastric CancerGastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd.90 enrolled12 locationsNCT06221748
Recruiting
Phase 1
Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression
Pancreatic CancerGastric CancerGastroesophageal Junction Adenocarcinoma+1 more
Suzhou Immunofoco Biotechnology Co., Ltd30 enrolled1 locationNCT05472857
Recruiting
Phase 3
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd.360 enrolled1 locationNCT06123494